Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer

NCT01270399 is registered in ClinicalTrials.gov with Meir Medical Center as lead sponsor.

NCT NCT01270399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01270399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer
Lead sponsor
Meir Medical Center
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2011
Completion date
January 31, 2013
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

the combined effect of hsp90 inhibitor and hdac/proteasome inhibitors on lung cancer cell fate and er-golgi homeostasis will be examined.